CollPlant Expands rhCollagen Distribution Network
Ticker: CLGN · Form: 6-K · Filed: Oct 27, 2025 · CIK: 1631487
Sentiment: neutral
Topics: distribution, press-release, biotechnology
TL;DR
CollPlant is broadening its reach for its collagen products, aiming for wider market access.
AI Summary
On October 27, 2025, CollPlant Biotechnologies Ltd. announced an expansion of its rhCollagen distribution network. The company issued a press release detailing this strategic move to broaden its market reach for its regenerative medicine products.
Why It Matters
Expanding distribution is crucial for CollPlant to increase sales and market penetration of its innovative regenerative medicine products, potentially leading to greater revenue and wider adoption in the healthcare sector.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant
- October 27, 2025 (date) — Date of press release
FAQ
What is the primary purpose of this 6-K filing?
This 6-K filing is a Report of Foreign Private Issuer, primarily to announce the expansion of CollPlant's rhCollagen distribution network via a press release issued on October 27, 2025.
What specific product is CollPlant expanding distribution for?
CollPlant is expanding the distribution for its rhCollagen products.
What is the filing date and period of report?
The filing was made on October 27, 2025, and the period of report is also October 2025.
Does CollPlant file annual reports under Form 20-F or 40-F?
CollPlant indicates it files annual reports under cover of Form 20-F.
Where is CollPlant Biotechnologies Ltd. headquartered?
CollPlant Biotechnologies Ltd. is headquartered at 4 Oppenheimer St, Weizmann Science Park, Rehovot 7670104, Israel.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2025-10-27 07:16:16
Filing Documents
- ea0262572-6k_collplant.htm (6-K) — 9KB
- ea026257201ex99-1_collplant.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- 0001213900-25-102345.txt ( ) — 52KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: October 27, 2025 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2